Medicine
Showing 121-130 of 162 Results
-
Julia D. Ransohoff
Instructor, Medicine - Oncology
BioDr. Ransohoff received her B.A. from Harvard College in Human Developmental and Regenerative Biology and completed her medical training at Stanford University, where she received her M.D., completed residency in internal medicine, and fellowship training in hematology and oncology as part of the American Board of Internal Medicine Physician Scientist Training Program.
Dr. Ransohoff is a physician-scientist dedicated to improving breast cancer treatments and outcomes through developing genomic methods to profile how tumors respond to treatment. Her research focuses on molecular approaches to understand the variable clinical responses of breast cancers to treatment at the genomic level by profiling molecular residual disease. Her current work involves exploring mechanisms of chemoresistance and immune evasion and identifying novel therapeutic targets. In related work, she also studies epidemiological risk factors for breast cancer mortality with a focus on the gut microbiome, oncofertility, and racial and ethnic differences in treatment response. Dr. Ransohoff's research has been supported by the ASCO Conquer Cancer Foundation, the Terri Brodeur Breast Cancer Foundation, the Stanford Cancer Institute, ECOG-ACRIN, and the Chan Zuckerberg Initiative.
As an Instructor in the Division of Medical Oncology, Dr. Ransohoff is also a clinically active oncologist, treating patients with breast cancer. -
Fauzia Riaz, MD, MHS
Assistant Professor of Medicine (Oncology)
BioDr. Riaz is advancing biomarker-driven precision medicine in breast cancer through innovative clinical trials that integrate cutting-edge therapeutics and molecular insights.
Her research focuses on circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) in early-stage breast cancer, aiming to guide personalized treatment strategies. She is also developing novel approaches to enhance immunotherapy efficacy by modulating the tumor microenvironment, including early-phase trials that combine immunotherapy with radiotherapy. As an Assistant Professor at Stanford University School of Medicine, Dr. Riaz is committed to ensuring that these next-generation therapies are accessible to all patients.. -
Sonia Rios-Ventura
Family Health Navigator, Medicine - Med/Oncology
BioSonia Rios-Ventura is a clinical research coordinator associate for the Stanford School of Medicine, department of Cancer Genetics and Genomics. She received her B.A. in anthropology and intensive sociology from the University of California Santa Cruz.
She is also the family health navigator for the Genetic Information and Family Testing (GIFT) Study. GIFT's mission is to help families beat cancer. It aims to save lives through education and communication about cancer risk and prevention in families. When someone learns they have a genetic mutation that increases their risk for cancer, it means their family members might also be at risk. For too long, the difficult job of talking about family cancer risk has fallen to the cancer patients alone. GIFT is here to make it easier for people to share this important information and give family members an easy way to get genetic testing to learn about their personal cancer risk. GIFT is an online program developed by cancer patients, family members, and doctors that offers a new way to, 1. Share life-saving information about family cancer risk and ways to lower that risk, 2.Connect interested family members to easy, at-home genetic testing. -
Rajat Rohatgi
Professor of Biochemistry and of Medicine (Oncology)
Current Research and Scholarly Intereststhe overall goal of my laboratory is to uncover new regulatory mechanisms in signaling systems, to understand how these mechanisms are damaged in disease states, and to devise new strategies to repair their function.
-
Mohana Roy, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in oncology, including in Carcinoma of Unknown Primary (CUP).
Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience, given how the complex process of getting cancer care can be made a bit more seamless. She is the Associate Medical Director for Quality at Stanford Cancer Center from 2022.
She had led major efforts in the cancer program including starting standardized discharge follow up for patients after hospitalization, starting same day clinical care at the cancer center, and also expediting care for patients with an unclear diagnosis of cancer but with suspected imaging concerns.
Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs), through distress screening with the Stanford Medicine Cancer Center, and in care for patient with limited English proficiency.
Dr. Roy received her medical degree from Albert Einstein College of Medicine, and then completed residency training at Beth Israel Deaconess Medical Center. She then completed fellowship training in Hematology and Oncology at Stanford, where she was chief fellow. -
Alexander Isaac Salter
Postdoctoral Medical Fellow, Oncology
Fellow in Medicine - Med/HematologyBioI am a clinical fellow in medical oncology at Stanford University whose long-term goal is to become a translational physician-scientist who develops curative cellular immunotherapies for solid tumors. As a graduate student, I conducted the first comprehensive signaling analyses of therapeutically engineered T cells, demonstrating that signal strength, rather than quality, is a key determinant of T cell function and fate. These findings helped inform the design of next-generation cellular immunotherapies, some of which are now in clinical trials. I also co-led a collaboration with Dr. David Baker’s laboratory at the University of Washington to engineer synthetic protein “logic gates” enabling combinatorial antigen recognition with high precision, offering a potential path to more safely target solid tumors. My doctoral research resulted in 16 publications, including four prominent first-, co-first-, or second-author papers in high-impact journals, several reviews and textbook chapters, and recognition on the Forbes 30 Under 30 List.
At Stanford, I focus on translating cellular therapies for thoracic and genitourinary malignancies. Under the mentorship of Drs. Crystal Mackall and Allison Betof Warner, I am developing CAR T cells for lung cancer in non- and never-smokers and serve as a sub-investigator on an upcoming first-in-human phase 1 trial of drug-regulatable CAR T cells for adults with advanced solid tumors. -
Anuja Anand Sathe
Instructor, Medicine - Oncology
Current Research and Scholarly InterestsI am interested in understanding the determinants of therapeutic resistance in cancer. I investigate the composition of the tumor microenvironment and adaptive responses to therapy using single-cell and spatial approaches.
